TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06198712: A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease

Sponsor: Forma Therapeutics, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 95 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,341,200

Rescue Site Savings

+$4,183,200

Unlock Full NCT06198712 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06198712 Rescue Dossier →